Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze the resistance mechanisms acquired after treatment with Osimertinib. Clinical outcomes and molecular results from re-biopsies at the time of osimertinib progression of EGFR T790M-mutated NSCLC patient were analyzed. Twenty-one patients with stage IV adenocarcinoma were included [median 69 years; 57.1% female; 85.7% never-smokers; 23.8% ECOG performance status (PS) ≥2]. Median PFS and OS were 13.4 (95% CI: 8.0-18.9) and 26.4 (95% IC: 8.9-43.8) months, respectively. At the time of analysis, 10 patients had tumor progression (47.6%). T790M loss occurred in 50%, being associated with earlier progression (median PFS 8.1 vs. 21.4 months, = 0.011). Diverse molecular alterations were identified, including C797S mutation ( = 1), PIK3CA mutation ( = 2), MET amplification ( = 1), CTNNB1 mutation ( = 1), and DCTN1-ALK fusion ( = 1). Histological transformation into small cell carcinoma occurred in one patient. This real-world life study highlights the relevance of re-biopsy at the time of disease progression, contributing to understand resistance mechanisms and to guide treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136429 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.602924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
BMC Med
October 2024
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Lazertinib is a new type of medicine that helps treat a kind of lung cancer called NSCLC, especially for people whose cancer got worse after other treatments.
- In a study with 78 patients, those taking lazertinib lived for an average of about 39 months and had good survival rates at 1, 2, and 3 years.
- The study found that checking for certain cancer genes in the blood can help predict how well patients will respond to lazertinib treatment.
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
Clin Transl Oncol
September 2024
Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan.
Background And Objectives: Genomic alterations after resistance to osimertinib therapy in advanced T790M-mutated non-small cell lung cancer (NSCLC) are complex and poorly understood. In this study, we aimed to detect these genomic alternations via comprehensive next-generation sequencing (NGS) of tissue and liquid biopsies.
Patients And Methods: From September 2020 to June 2021, 31 stage IIIB/IV T790M-mutated NSCLC patients who exhibited progressive disease after osimertinib therapy and provided written informed consent were recruited.
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung Cancer
September 2024
Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Article Synopsis
- The study analyzed the effectiveness of befotertinib, a drug for treating non-small cell lung cancer with EGFR T790M mutation, showing positive outcomes in patients with brain metastases and a manageable safety profile.
- Two groups of patients received different doses of the drug, and after tracking their progress for nearly four years, the overall survival rates were reported as 23.9 months and 31.5 months for the lower and higher doses, respectively.
- The results suggest that befotertinib offers significant overall survival benefits compared to other third-generation treatments, with adverse effects mostly manageable and in line with previous findings for similar cancer types.
Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data.
Transl Lung Cancer Res
April 2024
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Article Synopsis
- The T790M mutation in the epidermal growth factor receptor is important for predicting if certain lung cancer treatments will work, but not all patients with this mutation respond well to those treatments.* -
- A new method called "Mixture-of-experts" (MoE) combines different small models to spot patterns in T790M-mutated lung cancer patients, aiming to better predict how well they will respond to treatments.* -
- Research showed that using this new method helped predict treatment responses with good accuracy, and patients at low risk of not responding to treatment had a longer time without disease progression.*
Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Bioorg Chem
June 2024
Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang Jiangxi, 330013, China. Electronic address:
Mobocertinib, as a structural analog of the third generation TKI Osimertinib, can selectively act on the EGFRex20 mutation. We have structurally modified Mobocertinib to obtain new EGFR inhibitors. In this paper, we chose Mobocertinib as a lead compound for structural modification to investigate the effect of Mobocertinib derivatives on EGFR mutation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!